For herpes viruses (A61P31/22)

A   Human necessities(312083)
A61P31/22                     For herpes viruses(121)
Forzicyaside sulfate and its derivatives, method for its production and its application // 2642784
FIELD: pharmacology.SUBSTANCE: invention relates to forzicyaside sulfate and its derivative represented by the following formula , wherein R is Na+, K+ or NH+, and a method for their preparation, as well as an antiviral drug based on them and its use.EFFECT: increased efficiency of agents.10 cl, 9 tbl, 2 dwg
Cyclopropane carboxylate ethers of purine analogues // 2642463
FIELD: pharmacology.SUBSTANCE: invention relates to new cyclopropane carboxylate esters of purine analogues of the formula (T) or pharmaceutically acceptable salts thereof, which can be used for treatment of herpesvirus infections. Herpesvirus infection is an infection caused by the herpes simplex virus, infection of herpes zoster, or cytomegalovirus infection. In the compound of the formula (T) each Rx and Rz is independently hydrogen or (C1-C6)alkyl, or Rx is hydrogen and Rz is (C1-C6)alkyl, or Rx is (C1-C6)alkyl and Rz is hydrogen; and Ry is (C1-C6)alkyl, halo (C1-C6)alkyl, C6aryl, haloC6aryl or (C4-C5)heteroaryl with one heteroatom selected from nitrogen and oxygen in the ring.EFFECT: increased efficiency of compounds application.7 cl, 5 dwg, 3 tbl, 16 ex
ethod of obtaining live cultural attenuated vaccine for the prevention of varicella // 2637093
FIELD: medicine.SUBSTANCE: method of obtaining live cultural attenuated vaccine for the prevention of varicella includes infection with varicella-zoster virus strain of OKA diploid cells LEC-3 with the subsequent reproduction and the release of virus into cultural medium. Thereafter, at least one collection of the virus-containing liquid, the addition of a stabiliser and the preparation of the vaccine are carried out. The group of inventions also relates to the use of a strain of diploid LEC-3 cells for the production of a live cultural attenuated vaccine for the prevention of varicella. The use of diploid cells of strain LEC-3 with high adhesiveness to the surface of growth allows to obtain from 7 to 15 individual virus collections with a high content of extracellular vaccine Varicella zoster virus.EFFECT: obtaining extracellular virus Varicella zoster by individual collections from infected diploid cells LEC-3 using trisodium citrate provides increased harvest of Varicella zoster virus than in similar cultural models when used as a dispersant of trypsin.7 cl, 1 tbl, 3 dwg
Cream-milk for zoster treatment // 2634264
FIELD: pharmacology.SUBSTANCE: invention is a cream milk for the immediate relief of pain in the area of skin eruptions in the form of watery blisters arising during zoster, containing an oil phase, structure-forming emulsifiers and an aqueous phase with lidocaine hydrochloride and a softening agent, characterized by emollient sodium hydrogencarbonate application as the softening agent and aqueous phase containing ingredients at a certain ratio, wt %, at pH of 8.4 and osmotic activity less than 280 mOsmol/l of water.EFFECT: enveloping and softening effect, quickly dilutes dry crusts, thick serous fluid, pus and blood, facilitates their painless removal from the surface, promotes formation of a uniform film on the skin surface, which protects the skin from drying and irritation, makes it soft and elastic, reduces the value of the interstitial pressure, accelerates penetration of the local anesthetic into the tissue and its absorption into the blood.1 cl

Inactivated vaccines against varicella-zoster virus, methods for their production and application // 2633058
FIELD: pharmacology.SUBSTANCE: group of inventions can be used to produce a vaccine against the varicella zoster virus (VZV). The pharmaceutical composition comprises a therapeutically effective amount of an inactivated varicella-zoster virus (VZV) and a pharmaceutically acceptable carrier, wherein VZV is inactivated by gamma irradiation at a dose of 16 to 26 kGy and wherein the infectivity of VZV is ≤0.040 plaque forming units (PFU)/ml, and where the inactivated VZV elicits an immune response against VZV when administered to a patient. The group of inventions refers to a method for production of an inactivated vaccine against VZV, as well as a method for herpes zoster treatment in a patient, comprising pharmaceutical composition administration to the patient.EFFECT: use of this group of inventions allows to obtain a pharmaceutical composition that possesses a complex of two properties, safety of use in patients with weakened immunity and immunogenicity, the necessary dose of irradiation from 16 to 26 kGy ensures that these two criterial conditions are met.20 cl, 10 ex, 7 dwg

2-amino-5,6-difluor-1-(beta-d-ribofuranosyl)-benzimidazole, method for production and antiviral activity in terms of herpes simplex virus type i // 2629670
FIELD: pharmacology.SUBSTANCE: invention relates to a 2-amino-5,6-difluoro-1-(beta-D-ribofuranosyl)-benzimidazole of formula (I) suitable for treatment of herpes, and a method for its preparation that can be used in the pharmaceutical industry: (I). The proposed method involves ortho-phenylenediamine condensing with bromocyanide, followed by bromohydrate removal with sodium carbonate and a reaction of obtained base transribosylation with uridine in the presence of catalytic amounts of uridine phosphorylase and purine nucleoside phosphorylase.EFFECT: new effective anti-herpes virus compound is proposed, including that against variants of the virus resistant to the action of basic antiherpetic drugs, as well as a new effective method for obtaining.3 cl, 3 ex, 4 dwg

New 1-(-d-ribofuranosil-3-(5-substituted-1,2,4-oxadiazole-3-yl)-1,2,4-triazoles with anti-viral properties and method for their production // 2629360
FIELD: biotechnology.SUBSTANCE: invention relates to new antiviral derivatives of general formula: , where R is selected from H, CH3, CH(CH3)2, Ph, as well as to a process for their preparation that can be used in the pharmaceutical industry. The proposed production method involves introduction of isopropylidene and triphenylmethyl protecting groups into the glycosidic portion of ribavirin, dehydration of the carboxamide group into amidoxime, preparation of an O-acylated derivative with an amidoxime moiety followed by intramolecular cyclization to obtain a glycosidically protected ribavirin analogue having a 5-substituted-1,2,4-oxadiazole fragment at the 3rd position of 1,2,4-triazole, and subsequent removal of the isopropylidene and trimethylphenyl protecting groups.EFFECT: new compounds effective against herpes simplex virus type 1, influenza A virus and hepatitis C virus, as well as an effective way of their preparation, are proposed.3 cl, 12 ex, 6 dwg

5-(tetrahydrofuran-2-yl)-1,2,4-triazole-3-carboxylic acid amide with antiviral activity, and method for production // 2624018
FIELD: pharmacology.SUBSTANCE: invention relates to the 5-(tetrahydrofuran-2-yl)-1,2,4-triazole-3-carboxylic acid amide having selective antiviral activity against influenza A virus and herpes simplex virus of the first type having the structural formula . The invention also relates to a process for amide preparation.EFFECT: new compound with antiviral activity is obtained.2 cl, 2 dwg, 3 ex
Ophthalmic drops composition // 2623066
FIELD: pharmacology.SUBSTANCE: invention relates to a composition in the form of ophthalmic drops containing 2-amino-9-[[(1S,2R)-1,2-bis(hydroxymethyl)cyclopropyl]methyl]-1,9-dihydro-6H-purin-6-one and cyclodextrin, and to its use for the diagnosis and the treatment of the type 1 (FHV-1) feline herpes virus eye infection. The method for preparing an ophthalmic solution containing 2-amino-9-[[(1S,2R)-1,2-bis(hydroxymethyl)cyclopropyl]methyl]-1,9-dihydro-6H-purin-6-one and cyclodextrin.EFFECT: increasing the compound application effectiveness.20 cl, 9 ex
Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use // 2611437
FIELD: chemistry; pharmaceutics.SUBSTANCE: invention relates to novel compounds of formula (I) or its pharmaceutically acceptable salt or solvate, which have inhibiting activity lysine specific demethylase-1 (LSD1). In compounds of formula (I) (A) means phenyl or pyridyl, where said phenyl or pyridyl comprises n substitutes (R3); (B) means -O-CH2-phenyl or phenyl, where said phenyl or phenyl fragment, contained in the above -O-CH2-phenyl, comprises n substitutes (R2); (D) means a monocyclic heteroaryl group containing 5 or 6 ring members, where one to three said ring members are heteroatoms, selected from O, S and N, where said heteroaryl group contains one substitute (R1) and, besides, where said heteroaryl group is covalently bonded to molecules through circular carbon atom; (R1) means -NH2; each (R2) is independently selected from a group comprising C1-C6alkyl, hydroxy group, halogen, C1-C6haloalkyl, C1-C6haloalkyl oxy group or C1-C6alkoxy group; each (R3) is independently selected from a group comprising C1-C6alkyl, a hydroxy group, halogen, C1-C6haloalkyl, C1-C6haloalkyl oxy group or C1-C6alkoxy group; and n independently equal to 0, 1, 2 or 3.EFFECT: compounds can be used for treatment or preventing cancer, selected from a prostate cancer, breast cancer, lung cancer, colorectal cancer, cerebral cancer, blood cancer or leukemia; neurological diseases, including depression, Alzheimer's disease, Huntington's disease, Parkinson's Disease, amyotrophic lateral sclerosis, frontal-temporal dementia or dementia with Lewy bodies; or viral infection caused by herpes virus, or selected from a group of HSV-1, HSV-2, and Epstein-Barr virus.66 cl, 2 tbl, 38 ex
Pharmaceutical preparation for local application, containing b220 // 2608909
FIELD: pharmaceutics.SUBSTANCE: invention relates to pharmaceutical composition for local application for preventing or treating herpes virus infection in humans. Above composition contains 2,3-dimethyl-6-(N,N-dimethylaminoethyl)-6H-indolo-(2,3-b)quinoxaline (B-220) or its pharmaceutically acceptable salt in amount of 0.1–10 wt/wt% in pharmaceutically acceptable carrier.EFFECT: invention provides evident therapeutic effect of herpetic infection.5 cl, 1 ex

N-[5-(aminosulphonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate having specific particle size distribution range and specific surface area range for use in pharmaceutical formulations // 2606628
FIELD: chemistry.SUBSTANCE: present invention relates to a crystalline monohydrate of N-[5-(aminosulphonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide monomethanesulphonic acid of following formula , where particles of monohydrate of N-[5-(aminosulphonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide monomethanesulphonic acid have particle size ranging from 1 to 500 mcm, particle size distribution, which is determined in d (0.1) from 2 to 100 mcm, d(0.5) from 30 to 210 mcm and d(0.9) from 70 to 400 mcm, and specific surface area less than 1.0 m2/g. Invention also relates to a pharmaceutical composition for treating or preventing infectious diseases, containing crystalline particles of monohydrate of N-[5-(aminosulphonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide monomethanesulphonic acid, where particles of monohydrate of N-[5-(aminosulphonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide monomethanesulphonic acid have particle size ranging from 1 to 500 mcm, particle size distribution, which is determined in d(0.1) from 2 to 100 mcm, d(0.5) from 30 to 210 mcm and d(0.9) from 70 to 400 mcm, and specific surface area less than 1.0 m2/g, together with at least one pharmaceutically acceptable carrier, inert filler, solvent and/or diluent.EFFECT: novel form is characterised by improved properties in relation to stability and bioavailability.13 cl, 9 dwg, 10 tbl, 7 ex

ethod of treating generalized cytomegalovirus infection in children of early age // 2602953
FIELD: medicine.SUBSTANCE: invention relates to medicine and can be used for the treatment of generalized cytomegalovirus infection in children of early age. To do this, when viral load in blood is 105 cop/ml or more, child is subjected to intravenous introduction of ganciclovir for 14-21 days at a dose of 5-7.5 mg/kg to reduce the viral load in the blood to 104-103 cop/ml, then ganciclovir is withdrawn and viferon 150,000 ME in suppositories is used as follows: 1 suppository 2 times a day for 10-14 days, then 1 suppository 3 times a week: Monday, Wednesday, Friday for 3-6 months till complete elimination of virus in child's blood.EFFECT: invention provides complete elimination of the virus from the blood of the young child.1 cl, 4 tbl, 3 ex

ethod of increasing clinical immune efficiency of genital herpes therapy using intravascular blood laser exposure // 2602304
FIELD: medicine.SUBSTANCE: invention relates to medicine, specifically to immunology, and can be used for treating genital herpes. Method comprises intravascular laser therapy with underlying antiviral therapy at wave length 365 nm, radiation power at end of light guide 1 mW, exposure 8 minutes, course of 6 sessions.EFFECT: using given method enables to normalise clinical presentation, disappearance of clinical manifestations in observation period of up to one year, recovery of factors of antimicrobial protection, results are recorded in clinical-laboratory findings.1 cl, 2 tbl
Use of preparation laennek for treating a disease, associated with impaired immunity, which is a chronic recurrent herpes, atopic dermatitis or psoriasis // 2599038
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely dermatology and immunology. Use of Laennek as immunotropic preparation is disclosed for treating a disease, associated with impaired immunity, which is chronic recurrent herpes, atopic dermatitis or psoriasis, by drop intravenous introduction of Laennek 2 times a week in an amount of 10 procedures during integrated therapy, where the first drop introduction to patient is 4.0 ml Laennek dissolved in 200-250 ml of saline solution (0.9 % aqueous solution of sodium chloride) through ulnar vein for 1 hour 20 minutes, second and subsequent introduction contain 10.0 ml of Laennek dissolved in 250 ml of 0.9 % saline solution through ulnar vein for 1.5 hours.EFFECT: use of Laennek as immunotropic preparation is disclosed for treating a disease, associated with impaired immunity, which is chronic recurrent herpes, atopic dermatitis or psoriasis.1 cl, 3 ex

Vaccine against herpes simplex virus type 2: compositions and methods for triggering immune response // 2585961
FIELD: medicine; immunology.SUBSTANCE: group of inventions relates to medicine, specifically to immunology, and can be used to obtain a vaccine against herpes simplex virus (HSV). Drug comprises a pharmaceutically acceptable carrier and a polypeptide comprising amino acid sequence of SEQ ID NO. 2 or amino acid sequence SEQ ID NO. 2, wherein 1-20 amino acids are absent from N-terminus, C-terminus or both. Group of inventions also relates to use of isolated polypeptides for preparing a medicament for treating a patient from herpes simplex virus infection.EFFECT: use of this group of inventions enables to use isolated polypeptides represented by SEQ ID NO 2 separately or in a combination with SEQ ID NO 4 and SEQ ID NO 5 as an effective vaccine.138 cl, 16 tbl, 6 dwg

Antiviral composition // 2584245
FIELD: medicine.SUBSTANCE: invention relates to pharmaceutical industry, particularly to an agent for preventing or treating viral infection caused by herpes simplex virus (HSV). Extract from stem (trunk with bark), bark, branches and trunk bark plant Ficus arnottiana, resulting in a certain way, for prevention or treatment of a viral infection caused by herpes simplex virus (HSV). Composition comprising a therapeutically effective amount of an extract of the trunk (trunk bark), bark, twigs or stem bark plants Ficus arnottiana and a pharmaceutically acceptable carrier, for prevention or treatment of a viral infection caused by herpes simplex virus (HSV). A method for preparing the composition. Method of treating viral infection in a subject caused by herpes simplex virus (HSV), comprising a step in which a subject is administered said composition. Use of a composition for prevention or treatment of a viral infection caused by herpes simplex virus (HSV). Application isolated extract and a pharmaceutically acceptable carrier to produce a medicament for prevention or treatment of a viral infection caused by herpes simplex virus (HSV).EFFECT: agents described above are effective for preventing or treating a viral infection caused by herpes simplex virus (HSV).24 cl, 10 dwg, 4 tbl, 18 ex

Antiviral agent based on total amount of flavonoids from alchemilla vulgaris l // 2580304
FIELD: pharmaceutics.SUBSTANCE: invention refers to pharmaceutical industry, namely, to application of the sum of flavonoids of roots or above-surface parts of Alchemilla vulgaris L. as an antiviral agent apropos RNA-containing virus of flu A and DNA-containing orthopoxviruses and virus of herpes simplex of type 2. Use of the the sum of flavonoids of roots and above-surface parts of Alchemilla vulgaris L. (alchemillae Herba) obtained by extraction of roots with the help of ethyl acetate, combination of ethyl acetate extract, concentration of it by evaporation and deposition of the concentrate in chloroform or extraction of an elevated part of alchemillae Herba collected at the beginning of blooming by ethanol, followed by combination and evaporation of the extract, dilution of it with distilled water, cleaning of the water extract with chloroform, extraction of the purified water residue with ethyl acetate, evaporation of the obtained extract and deposition of the product with chloroform under certain conditions as an antiviral agent apropos RNA-containing virus of flu A and DNA-containing orthopoxviruses of herpes simplex of type 2.EFFECT: above described sum of flavonoids is effective as an antiviral agent apropos RNA-containing virus of flu A and DNA-containing orthopoxviruses of herpes simplex of type 2.1 cl, 7 tbl, 7 ex
Film-forming composition and use thereof for treating herpes // 2578959
FIELD: pharmaceutics.SUBSTANCE: invention relates to pharmaceutical industry and is a film-forming composition for treatment of herpes, in particular herpes labialis, comprising a pharmaceutically acceptable medium 5 to 30 wt% ethyl cellulose, from 0.1 to 20 wt% castor oil as an auxiliary film-forming agent, from 0.1 to 5 wt% boric acid and mixtures of citric acid and from 60 to 85 wt% of ethanol as an organic solvent, where weight percentages are based on weight of relative total weight of composition.EFFECT: invention provides a solid formation of airtight film and wider range of means of treating herpes on lips.8 cl, 3 ex, 2 tbl

Bis(5-amino-1,4-dioxo-1,2,3,4-tetrahydrophthalazin-2-yl)zinc, method for producing it, based pharmaceutical composition, based therapeutic agents, method of treating skin diseases and method of treating gastritis // 2577849
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to medicine, particularly to a compound representing bis(5-amino-1,4-dioxo-1,2,3,4-tetrahydrophthalazin-2-yl)zinc of formula (I) . Use of the compound of formula (I) (versions), a method for producing it, a based pharmaceutical composition, methods of treating skin diseases and gastritis are also presented.EFFECT: invention enables producing the compound of formula (I), which provides relieving or eliminating negative consequences of skin and mucosal injuries.63 cl, 27 dwg, 6 tbl, 13 ex

ethod of reducing rate of recurrences and intensity of symptoms of genital herpes // 2577718
FIELD: medicine.SUBSTANCE: invention is a method for reducing frequency of relapses and symptoms of genital herpes, which consists in ingestion of acyclovir 3 times a day 400 mg for 10 days and then, starting from 11th - 15th day from start of treatment with acyclovir, three times, with 21 day intervals, means introducing an aqueous solution containing at least 90 wt% sodium monophosphate polyprenol of general formula H-[-CH2-C=CH-CH2-]a-XNa2, wherein X - an anion of phosphoric acid, and not more than 10 wt% sodium pyrophosphate polyprenol of general formula H-[-CH2-C=CH-CH2-]a-YNa2, wherein Y - anion pyrophosphoric acid, and - at least 7, intramuscularly at a dose of 8 mg per 2.0 ml.EFFECT: invention ensures reduction of frequency of recurrent genital herpes with simultaneous reduction of intensity of symptoms: itching, pain and burning.1 cl, 1 tbl, 2 dwg

Herpetic fever virus vaccines // 2575067
FIELD: biotechnologies.SUBSTANCE: replication-deficient, dominant and negative recombinant virus of herpetic fever 2, the vaccine and the method of patient immunisation against the infection HSV-1 or HSV-2 are offered. The recombinant virus contains two sequences coding D HSV-2 glycoprotein, linked with ICP4 promoters in the genome, the latter are connected with the sequences of tetracycline operators, and two sequences coding UL9-C535C protein which are linked with hCMV promoters linked with the sequences of tetracycline operators. Note that the virus doesn't contain the sequence coding ICP0 protein. The vaccine containing the named recombinant virus is safe and efficient against the infections HSV-1 or HSV-2 due to expression of the dominant and negative form of UL9-C535C polypeptide and use of tetracycline-induced activation and deactivation of genes. The method of immunisation of patients against HSV-1 or HSV-2 using the offered vaccine is also offered.EFFECT: offered vaccine and the method of patient immunisation can be used in medicine for transformation or suppression of breakout of HSV-1 or HSV-2.17 cl, 19 dwg, 1 tbl, 1 ex

4,6-di(3,12-diaza-6,9-diazoniadispiro[5,2,5,2]hexadecan-1-yl)-2-methyl-5-nitropyrimidine tetrachloride hydrochloride hexahydarate for treating herpetic infection, pharmaceutical composition for local application // 2573977
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to medicine and represents a pharmaceutical composition in the form of a cream or gel for treating a herpes viral infection, containing 4,6-di(3,12-diaza-6,9-diazoniadispiro[5,2,5,2]hexadecan-1-yl)-2-methyl-5-nitropyrimidine tetrachloride dihydrochloride hexahydrate. The invention consists in a method of treating or preventing a herpetic infection in a human or animal.EFFECT: providing a pharmaceutical composition of 4,6-di(3,12-diaza-6,9-diazoniadispiro[5,2,5,2]hexadecan-1-yl)-2-methyl-5-nitropyrimidine tetrachloride dihydrochloride hexahydrate in the form of a dosage form for local application possessing a high level of therapeutic efficacy.4 cl, 2 dwg, 2 tbl, 5 ex

ethod for prevention of neutropenia in patients suffering chronic hepatitis c and receiving antiviral combination therapy // 2568894
FIELD: medicine.SUBSTANCE: invention may be applicable to prevent neutropenia developing in the patients suffering chronic hepatitis C (CHC) in response to conducting an antiviral combination therapy (ACT). The method for preventing neutropenia in the CHC patients receiving the ACT is characterised by introducing autoblood haemolysate (ABH) 20.0 ml intravenously daily to the CHC patients in need of the ACT and having a high risk of ACT-associated neutropenia, 10 days exactly before the ACT beginning; from the very beginning and throughout the entire course of the ACT, the ABH intravenous administration continues in the same dose, however performed every 7 days. During the ABH intravenous administration, patient's blood 10.0 ml is taken from median cubital vein into a syringe 20.0 ml 50% pre-filled with distilled water; thereafter, leaving a puncture needle in the vein, the ABH produced in the syringe is introduced back into the vascular bed.EFFECT: method enables the effective prevention of neutropenia accompanying the ACT in the CHC patients with the use of the autoblood haemolysate.1 tbl, 1 ex
Pharmaceutical composition for treating herpetic infections // 2560686
FIELD: medicine.SUBSTANCE: as active agents, the composition contains triazavirin in an amount of 1.5-2.0 wt % and sea buckthorn oil in an amount of 1.5 - 2.0 wt %, whereas a gel base represents silicone glycerohydrogel Si(C3H7O3)4·6C3H8O3·24H2O.EFFECT: invention has high therapeutic activity and an increased rate of pathological element epithelisation alongside with no adverse side effect.5 ex
Pyroxicam for preventive and therapeutic treatment of hypervirus infections // 2555765
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to pharmaceutical industry and represents medication, possessing virucidal activity, for preventive and therapeutic treatment of viral infections, caused by virus of herpesviridae family, characterised by the fact that said medication contains pyroxican in carrier substance.EFFECT: invention provides extension of arsenal of means, possessing virucidal activity.7 cl

ethod of treating epstein-barr viral infection in hiv-infected children // 2555474
FIELD: medicine.SUBSTANCE: treating an active form of Epstein-Barr viral infection in the children with an inactive HIV infection involves conducting high-active antiretroviral therapy accompanying administering inosin pranobex prescribed orally from the first day of treatment in a daily dose of 50 mg/kg of body weight, 3-4 times a day to make three courses of 10 days each, as well as using suppositories of interferon alpha-2b + taurine per rectum according to the schedule: for the first 10 days of treatment - one suppository two times a day - in the morning and in the evening, every 12 hours; further - one suppository at the bedtime every second day for three months. The method enables reducing a rate and an intensity of the Epstein-Barr viral infection symptoms by reducing the lymphocyte, blood plasma, oropharyngeal mucus Epstein-Barr virus content and improving the immunological status presented by normalising CD3+ lymphocyte, CD4+ lymphocyte, CD95+ lymphocyte, annexin-V+ lymphocyte, annexin-V+/propidium+ lymphocyte, CD19+ lymphocyte counts.EFFECT: reducing the rate and intensity of symptoms.2 tbl, 2 ex
Pharmaceutical composition for producing antiherpetic mixed vaccine and based dosage form // 2552341
FIELD: medicine.SUBSTANCE: pharmaceutical composition contains a viral preparation containing types 1 and 2 herpes simplex viruses inactivated by formalin or gamma radiation, and an immunocompetent substance. The immunocompetent substance is presented by interferon and a combination of at least two independent amino acids in the following proportions: inactivated types 1 and 2 herpes simplex viruses - 5 mln of plaque-forming units per 1 ml of the suspension, interferon - 150-250 thousand International units/ml, amino acids - 0.27 mg/ml.EFFECT: adding interferon to the composition as an adjuvant, and also a combination of two irreplaceable amino acids enables creating the high-effective herpes vaccine, preparing a based dosage form in the form of suppositories that makes the vaccine applicable in paediatric practice.4 cl, 3 ex
Treating viral infections // 2545918
FIELD: medicine.SUBSTANCE: invention provides a stable composition for treating damages associated with herpes-virus infections in a form specified in creams and gels containing low-level trichloroacetic acid. The amount of trichloroacetic acid makes less than 6% (wt / wt) of the cream or gel.EFFECT: extending the range of products for treating the damages associated with herpes-virus infections.25 cl, 3 ex

New therapeutic agents for local administration based on sulphated hyaluronic acid as cytokine activity stimulators or inhibitors // 2543354
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmaceutical industry and represents using sulphated hyaluronic acid for preparing a therapeutic agent for local administration for treating inflammatory/irritating skin diseases specified in dermatitis, atopic dermatitis, photocontact dermatitis, rash, vitiligo, eczema, psoriasis, all skin irritations related to activation of anti-inflammatory cytokines, such as IL-1, IL-2, IL-7, IL-8, IL-9 and TNF, wherein hyaluronic acid has a molecular weight falling within the ranges of 10000 D to 50000 D, 150000 D to 250000 D and 500000 D to 750000 D, and a sulphatation degree equal to 1.EFFECT: invention provides stimulating the immune system protein synthesis for eliciting the immune response.8 cl, 33 ex, 15 dwg, 3 tbl

A-seco-triterpenoids with methylketone fragment // 2537840
FIELD: chemistry.SUBSTANCE: invention relates to A-seco-triterpenoids of general formula (I) , where or , demonstrating inhibiting activity with respect to type I herpes simplex virus (HSV-1, strain 1C) and HIV-1. In addition, compounds (I) can be used as intermediates for other biologically active compounds.EFFECT: increased efficiency of compound application.2 cl, 1 tbl, 6 ex
Pharmaceutical composition containing lysine and enzymes: lysozyme, deoxyribonuclease and/or peroxidase for external treatment and prevention of infections caused by type 1, 2 herpes viruses, and bacterial complications caused by herpetic infection // 2535053
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to the pharmaceutical industry and represents a composition for the external treatment and prevention of infections caused by the type 1, 2 herpes virus and bacterial complications caused by the herpetic infection, containing lysozyme, peroxidase, povyargol as active ingredients, escin and glycyrrhizinic acid or its salts as anti-inflammatory ingredients, liposomes on the basis of high-active hydrated lecithin in a combination with cholesterol as carriers and pharmaceutically acceptable carriers and excipients, with the ingredients of the composition being taken in certain proportions, wt %.EFFECT: invention provides extending the range of products for treating and preventing the infections caused by type 1, 2 herpes virus and bacterial complications caused by the herpetic infection.4 ex, 1 tbl

Using polycarboxylic fullerene deriative as microbiocidal antiviral agent // 2533232
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to medicine, namely to using a polycarboxylic fullerene C60 derivative as a microbiocidal antiviral agent for the herpes simplex virus (HSV) and cytomegalovirus (CMV) inhibition. The polycarboxylic fullerene C60 derivative has the structural formula .EFFECT: invention provides the agent for the emergency prevention of HSV and CMV sexual transmission.7 dwg, 2 tbl, 5 ex

ethod of treating skin and mucosal diseases caused by herpes simplex viruses type 1 and type 2 // 2530587
FIELD: medicine.SUBSTANCE: invention refers to a method of treating recurrent skin and mucosal diseases caused by herpes simplex viruses type 1 and type 2 by coating a damaged region with a preparation containing a base including an active substance - (2,6-dichlorophenyl)amide carbopentoxysulphanic acid of the general formula: wherein X is Na, K, NH4, 2 times a day for 3-5 days, and if observing precursory symptoms, a repeated course of coating with the preparation is performed 1-2 times a day for 2-3 days.EFFECT: invention provides higher clinical effectiveness in recurrent skin and mucosal diseases caused by herpes simplex viruses type one and type two.2 cl, 4 ex
Drug preparation in suppositories for infectious-inflammatory disorders caused by type 1 herpes simplex and cytomegalovirus, and method for using it for treating children // 2521272
FIELD: medicine.SUBSTANCE: invention represents a drug preparation for treating diseases caused by type 1 herpes simplex and cytomegalovirus, containing recombinant human interferon 2α, lisocyme, Licopid, carnitine 20%, vitamin E and a fatty base.EFFECT: higher clinical effectiveness and reduced length of treatment, prolonged intercurrent periods, lower recurrent rate by prophylactic administration, reduced manifestation of neurotoxic effects of herpes viruses, lower administration of antibiotics for preventing bacterial complications in infectious-inflammatory diseases caused by herpes simplex virus and cytomegalovirus in children.2 cl, 3 tbl
ethod for assessing decay of fatty acid peroxide content in pregnant women's peripheral blood in third trimester of gestation with herpes virus infection by human immunoglobulin therapy // 2517067
FIELD: medicine.SUBSTANCE: invention may be used to reduce a risk of damaging cell membranes of the foetoplacental organs in the third trimester of gestation with aggravated herpes virus infection in the 12th week of gestation. That is ensured by an intravenous drop-by-drop infusion of human immunoglobulin 25 drops in the 16th and 24th weeks of pregnancy three times every second day.EFFECT: method enables preventing damaging the cell membranes of the foetoplacental organs by reducing the fatty acid peroxide content in peripheral blood.
ethod for vaccine therapy of herpetic infection // 2514034
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to methods for a vaccine therapy of herpetic infection. For this purpose, antigen-presenting dendritic cells (DC) taken from patient's blood are loaded with viral antigens that are originally found in a standard anti-herpetic vaccine representing suspended formalin-killed type I and II viruses of herpetic fever. The prepared vaccine is administered into the patient intracutaneously in 4-6 points along lymphatic collectors. The vaccine therapy course consists of 3-4 injections. A vaccine dosage interval makes 2 to 4 weeks. An initial vaccine dose makes 1×106-2×106 DC; for the second administration, the dose is increased twice; for the third administration the dose is increased 4 times as compared to the first administration.EFFECT: invention enables providing vaccination both in the acute period, and in the remission, as well as prolonging the remission three times by reducing a recurrence rate.1 ex, 2 tbl

Treating virus-induced injuries // 2506951
FIELD: medicine.SUBSTANCE: present invention refers to medicine, namely to dermatology, and may be used for treating skin injuries in an individual, wherein the above injuries are caused by a virus. For this purpose, ingenol compounds or a pharmaceutically acceptable salt thereof are administered.EFFECT: method provides the effective treatment ensured by the targeted action of the ingenol compounds on the virus-containing cells.19 cl, 13 tbl

Composition containing hcmv particles // 2505314
FIELD: medicine.SUBSTANCE: compositions contain an agent specified in a group consisting of HCMV virions, HCMV and NIEP HCMV solid corpuscles; the composition is able to elicit an immune response, whereas the virions, NIEP and/or solid corpuscles are not able to fuse. What is declared is a method for preparing the composition, as well as using the agent specified in a group consisting of the HCMV virion, HCMV and NIEP HCMV solid corpuscle; the agent is not able to fuse for preparing a vaccine.EFFECT: preparing the composition possessing no residual infectivity, however eliciting the immune response comprising the neutralising antigen antibody.43 cl, 2 tbl, 2 ex, 19 dwg
ethod of preventing antenatal fetus infection // 2504364
FIELD: medicine.SUBSTANCE: invention relates to field of medicine, namely to obstetrics and gynecology, and can be applied for prevention of antenatal infection of fetus by herpes simplex virus. For this purpose local and system episodic treatment with Acyclovir is carried out in case of herpetic infection relapse. In addition, antihomotoxic therapy is carried out by medicine Engistol for three months at pregravidal stage in women infected by virus herpes simplex. Dose of intake for the first month is 1 pill 3 times per day, for the second month - 1 pill 2 times per day, third month - 1 pill 1 time per day; and in the period of gestation in form of tree courses of antihomotoxic therapy by medication Engistol in dose 1 pill 3 times per day in terms 14-18 weeks, 24-28 weeks, 34-38 weeks of pregnancy.EFFECT: method is non-invasive, safe for the health of pregnant woman and fetus, available for institution of obstetrics, increases efficiency of prevention of antenatal fetus infection.
Antiherpetic agent // 2502504
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to agent possessing antiviral action, and may be used for treating herpes infections, including lip sore. The given agent contains the ingredients, wt %: a solution readily permeable through biological membranes of soapy amphiphilic complex of high-polymer RNA of Saccharomyces cerevisiae and oleic acid (as an interferon inducer) - 49.96; Vaseline oil - 20; Tween-80 - 17; Emulsifier T-2 - 13; Chlorhexidine Bigluconate - 0.04.EFFECT: preparation shows high antiherpetic activity, good tolerability and ability to reduce a recurrence rate considerably.

Triterpenoids with eh-nitrile fragment in a-pentacycle // 2496785
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to A-pentacyclic triterpenoids of general formula: , wherein R=H, R1= , or ; R=NH2, R1= or .EFFECT: compounds exhibit antiviral activity, including against type I herpes simplex virus (HSV-1, strain 1 C), HSV-1 and HIV-1, and may be also used as intermediates for new biologically active compounds.3 cl, 2 tbl, 7 ex

ethod of producing novel polymer compound, having antiviral activity by copolymerisation of 2,5-dihydroxybenzoic acid and gelatine using laccase enzyme // 2494119
FIELD: chemistry.SUBSTANCE: invention relates to chemical engineering and techniques for producing veterinary, medical and pharmaceutical preparations. The method of producing a novel antiviral substance based on 2,5-dihydroxybenzoic acid and gelatine includes oxidising 2,5-dihydroxybenzoic acid with laccase enzyme to intermediate phyenoxy radicals and semiquinones, which are then copolymerised with gelatine, and separating the obtained copolymer from low-molecular weight components by dialysis; optimum concentrations of components of the reaction mixture are as follows: 2,5-dihydroxybenzoic acid - 15-80 mM, gelatine - 1-13 mg/ml reaction mixture, laccase - 0.5-10 units of activity/ml reaction mixture.EFFECT: obtained copolymer has antiviral activity on herpesvirus, particularly Aujeszky's disease virus.2 tbl, 1 dwg, 3 ex

ethod of treating recurrent genital herpes with chronic fatigue symptoms // 2492861
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to dermatovenerology, and may be used for treating recurrent genital herpes with the chronic fatigue syndrome symptoms. That is ensured by administering an interferon inducer intramuscularly presented by high-polymer RNA in a dose of 8 mg every 72 hours for 10 days in a combination with oral administration of the antiviral drug Acyclovir 200 mg five times daily for 10 days. The other therapeutic regimen involves oral administration of the liposomal high-polymer RNA (Akaviya) daily 6.5 mg twice a day for 5 days, followed by the maintenance therapy in a dose of 6.5 mg every second day for 20 days and oral administration of Acyclovir 200 mg five times daily for 10 days.EFFECT: method provides an effective treatment of the herpes infection and the disappearance of the symptoms that characterise chronic fatigue syndrome, due to the normalising the immune status: higher CD3+ and CD4+ lymphocyte count, higher blood ά and γ interferon, blood herpes virus elimination that promotes the general state recovery in the female patients.9 tbl

Cytomegalovirus vaccine and method for preparing it // 2491340
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to vaccinology and cell biology.EFFECT: what is presented is a method for preparing the cytomegalovirus vaccine ensured by specifying a cell type wherein this virus replicates; the vaccine and method for immunising an individual against CMV.19 cl, 6 dwg, 5 tbl, 1 ex

Complexes of germanium with purine nitrogenous bases, methods for production thereof and medicinal agents containing said complexes // 2487878
FIELD: chemistry.SUBSTANCE: disclosed are germanium complexes, having a general structural formula (I): Gex[AD][CA]y[AA]z (I), where AD denotes a purine nitrogenous base derivative, having antiviral activity; CA denotes a hydroxycarboxylic acid; AA denotes an amino acid selected from α-amino acids, where x=1÷2, y=2÷4, z=0÷2, wherein all CA in the complex are identical or different, all AA in the complex are identical or different. Also disclosed is a method of producing germanium complexes, a medicinal agent and an immunostimulant.EFFECT: invention enables to obtain germanium complexes, having high antiviral and immunostimulating activity.18 cl, 5 dwg, 3 tbl, 7 ex

ethod for immunotherapy of chronic refractory herpes virus infection // 2485962
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to clinical Immunology and Infectious diseases, and may be used for treating chronic refractory herpes virus infection. That is ensured by using autologous IFN-alpha induced dendritic cells loaded with recombinant herpes virus antigen and administered to the patient subcutaneously by two courses in a combination with a preparation of recombinant interleukin-2 as an adjuvant.EFFECT: method enables reducing a number of recurrences and a severity of clinical manifestations of herpes virus infection ensured by induction of the effective antigen-specific cell-mediated response and maintaining it at an adequate level for a long period of time.1 ex, 1 dwg
ethod of treating herpetic stomatitis in hiv-patients // 2483766
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely dentistry, and may be used for treating herpetic stomatitis in HIV-patients. That is ensured by conducting a therapy that involves anti-herpetic, analgesic and anti-inflammatory preparations. From the very beginning of the therapy, the 2-week oral administration of glyciram 0.05-0.01 g is prescribed 2-4 times a day after a meal. In addition, the oral mucosa is topically exposed to low-frequency ultrasound oscillations with amplitude of oscillation 30-35 mcm, with frequency of cavitation 24.5-28.5 kHz for the first minute through an aqueous solution of glyciram. The aqueous solution of glyciram is prepared in advance at 0.025 mg of glycyram granules per 100 ml of warm boiled water. The therapeutic course is 10-14 ultrasonic procedures.EFFECT: method provides the increased clinical effectiveness ensured by eliminating the side effects and reducing the severity of the disease.2 ex

Use of liophilised preparation of allofibroblasts for treating herpes virus diseases // 2483739
FIELD: medicine.SUBSTANCE: invention refers to medicine and veterinary science, and is intended for treating herpes virus diseases. A lyophilised preparation of allofibroblasts is used as an antiviral agent.EFFECT: invention is effective for treating herpes virus of human and vertebrate animals.6 tbl, 4 ex

ethod of treating papilloma viral infections implemented through interleukin-18 induction // 2482866
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to dermatovenerology and may be used to treat the infections caused by human papilloma viruses, implemented through interleukin-18 induction. For this purpose, the inducer is presented by medicines of the peptide alloferon using the mechanical removal of any type of papilloma formation. The inducer is presented by injections of the preparation 'Allokin-alpha lyophilisate for solution for subcutaneous administration'; the therapeutic course is 3 injections every second day, and the course may be repeated. The inducter is presented by alloferon suppositories. The inducers are presented by the ointments containing alloferon.EFFECT: method provides the effective treatment ensured by the stimulation of natural immunity through interleukin-18 induction.4 cl, 3 tbl, 4 ex
 
2551013.
Up!